-
1
-
-
84892805731
-
Cancer statistics, 2014
-
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
-
(2014)
CA Cancer J Clin
, vol.64
, pp. 9-29
-
-
Siegel, R.1
Ma, J.2
Zou, Z.3
Jemal, A.4
-
5
-
-
84875840492
-
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 noninferiority trial
-
Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 noninferiority trial. Lancet 2013; 381: 1203-1210.
-
(2013)
Lancet
, vol.381
, pp. 1203-1210
-
-
Rummel, M.J.1
Niederle, N.2
Maschmeyer, G.3
-
6
-
-
84900423736
-
Randomized trial of bendamustinerituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
-
Flinn IW, van der Jagt R, Kahl BS et al. Randomized trial of bendamustinerituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123: 2944-2952.
-
(2014)
Blood
, vol.123
, pp. 2944-2952
-
-
Flinn, I.W.1
van der Jagt, R.2
Kahl, B.S.3
-
7
-
-
84872054301
-
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
-
Delarue R, Haioun C, Ribrag V et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 2013; 121: 48-53.
-
(2013)
Blood
, vol.121
, pp. 48-53
-
-
Delarue, R.1
Haioun, C.2
Ribrag, V.3
-
8
-
-
84864715966
-
Treatment of older patients with mantle-cell lymphoma
-
Kluin-Nelemans HC, Hoster E, Hermine O et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520-531.
-
(2012)
N Engl J Med
, vol.367
, pp. 520-531
-
-
Kluin-Nelemans, H.C.1
Hoster, E.2
Hermine, O.3
-
9
-
-
79959576404
-
Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report
-
Witzig TE, Fishkin P, Gordon LI et al. Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leuk Lymphoma 2011; 52: 1188-1199.
-
(2011)
Leuk Lymphoma
, vol.52
, pp. 1188-1199
-
-
Witzig, T.E.1
Fishkin, P.2
Gordon, L.I.3
-
10
-
-
0037262242
-
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo
-
Lentzsch S, LeBlanc R, Podar K et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003; 17: 41-44.
-
(2003)
Leukemia
, vol.17
, pp. 41-44
-
-
Lentzsch, S.1
LeBlanc, R.2
Podar, K.3
-
11
-
-
33745961875
-
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
-
Chang DH, Liu N, Klimek V et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006; 108: 618-621.
-
(2006)
Blood
, vol.108
, pp. 618-621
-
-
Chang, D.H.1
Liu, N.2
Klimek, V.3
-
12
-
-
33744536515
-
Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly
-
Gandhi AK, Kang J, Naziruddin S et al. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 2006; 30: 849-858.
-
(2006)
Leuk Res
, vol.30
, pp. 849-858
-
-
Gandhi, A.K.1
Kang, J.2
Naziruddin, S.3
-
13
-
-
65549151712
-
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction
-
Gorgun G, Ramsay AG, Holderried TA et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA 2009; 106: 6250-6255.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 6250-6255
-
-
Gorgun, G.1
Ramsay, A.G.2
Holderried, T.A.3
-
14
-
-
73949116990
-
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
-
Ramsay AG, Clear AJ, Kelly G et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009; 114: 4713-4720.
-
(2009)
Blood
, vol.114
, pp. 4713-4720
-
-
Ramsay, A.G.1
Clear, A.J.2
Kelly, G.3
-
15
-
-
33846665934
-
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
-
Verhelle D, Corral LG, Wong K et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67: 746-755.
-
(2007)
Cancer Res
, vol.67
, pp. 746-755
-
-
Verhelle, D.1
Corral, L.G.2
Wong, K.3
-
16
-
-
69549116054
-
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
-
Zhang L, Qian Z, Cai Z et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009; 84: 553-559.
-
(2009)
Am J Hematol
, vol.84
, pp. 553-559
-
-
Zhang, L.1
Qian, Z.2
Cai, Z.3
-
17
-
-
51649123319
-
Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells
-
Wu L, Adams M, Carter T et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008; 14: 4650-4657.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4650-4657
-
-
Wu, L.1
Adams, M.2
Carter, T.3
-
18
-
-
28844472902
-
Lenalidomide and thalidomide: mechanisms of action-similarities and differences
-
Anderson KC. Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin Hematol 2005; 42: S3-S8.
-
(2005)
Semin Hematol
, vol.42
, pp. S3-S8
-
-
Anderson, K.C.1
-
20
-
-
79952106893
-
Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo
-
Qian Z, Zhang L, Cai Z et al. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 2011; 35: 380-386.
-
(2011)
Leuk Res
, vol.35
, pp. 380-386
-
-
Qian, Z.1
Zhang, L.2
Cai, Z.3
-
21
-
-
84873076585
-
Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
-
Zhang LH, Kosek J, Wang M et al. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol 2013; 160: 487-502.
-
(2013)
Br J Haematol
, vol.160
, pp. 487-502
-
-
Zhang, L.H.1
Kosek, J.2
Wang, M.3
-
22
-
-
84862152044
-
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
-
Yang Y, Shaffer AL 3rd, Emre NC et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21: 723-737.
-
(2012)
Cancer Cell
, vol.21
, pp. 723-737
-
-
Yang, Y.1
Shaffer, A.L.2
Emre, N.C.3
-
24
-
-
73949145763
-
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma
-
Witzig TE, Wiernik PH, Moore T et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009; 27: 5404-5409.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5404-5409
-
-
Witzig, T.E.1
Wiernik, P.H.2
Moore, T.3
-
25
-
-
54449095901
-
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
-
Wiernik PH, Lossos IS, Tuscano JM et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4952-4957.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4952-4957
-
-
Wiernik, P.H.1
Lossos, I.S.2
Tuscano, J.M.3
-
26
-
-
64149112784
-
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
-
Habermann TM, Lossos IS, Justice G et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009; 145: 344-349.
-
(2009)
Br J Haematol
, vol.145
, pp. 344-349
-
-
Habermann, T.M.1
Lossos, I.S.2
Justice, G.3
-
27
-
-
79959722615
-
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
-
Witzig TE, Vose JM, Zinzani PL et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622-1627.
-
(2011)
Ann Oncol
, vol.22
, pp. 1622-1627
-
-
Witzig, T.E.1
Vose, J.M.2
Zinzani, P.L.3
-
28
-
-
84887030194
-
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
-
Zinzani PL, Vose JM, Czuczman MS et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 2013; 24: 2892-2897.
-
(2013)
Ann Oncol
, vol.24
, pp. 2892-2897
-
-
Zinzani, P.L.1
Vose, J.M.2
Czuczman, M.S.3
-
29
-
-
84889099537
-
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study
-
Goy A, Sinha R, Williams ME et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013; 31: 3688-3695.
-
(2013)
J Clin Oncol
, vol.31
, pp. 3688-3695
-
-
Goy, A.1
Sinha, R.2
Williams, M.E.3
-
30
-
-
84941625318
-
Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma
-
ASCO Annual Meeting Abstracts
-
Witzig TE, Vose J, Zinzani PL et al. Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. J Clin Oncol 2013; 31 (suppl; Abstract 8533; ASCO Annual Meeting Abstracts).
-
(2013)
J Clin Oncol
, vol.31
-
-
Witzig, T.E.1
Vose, J.2
Zinzani, P.L.3
-
31
-
-
84941663404
-
Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: a combined analysis from the MCL-001, NHL-002, and NHL-003 studies
-
EHA Annual Meeting Abstracts
-
Witzig TE, Vose J, Zinzani PL et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: a combined analysis from the MCL-001, NHL-002, and NHL-003 studies. Haematologica 2013; 98 (suppl; Abstract P305; EHA Annual Meeting Abstracts).
-
(2013)
Haematologica
, vol.98
-
-
Witzig, T.E.1
Vose, J.2
Zinzani, P.L.3
-
32
-
-
84975856533
-
Lenalidomide monotherapy is clinically active in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): a pooled analysis of data from phase II studies (NHL-002/003)
-
EHA Annual Meeting Abstracts
-
Czuczman M, Vose J, Zinzani PL et al. Lenalidomide monotherapy is clinically active in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): a pooled analysis of data from phase II studies (NHL-002/003). Haematologica 2010; 95: (suppl 2; EHA Annual Meeting Abstracts).
-
(2010)
Haematologica
, vol.95
-
-
Czuczman, M.1
Vose, J.2
Zinzani, P.L.3
-
33
-
-
84866875871
-
Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences
-
Eve HE, Carey S, Richardson SJ et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012; 159: 154-163.
-
(2012)
Br J Haematol
, vol.159
, pp. 154-163
-
-
Eve, H.E.1
Carey, S.2
Richardson, S.J.3
-
34
-
-
84881664038
-
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation
-
Vose JM, Habermann TM, Czuczman MS et al. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol 2013; 162: 639-647.
-
(2013)
Br J Haematol
, vol.162
, pp. 639-647
-
-
Vose, J.M.1
Habermann, T.M.2
Czuczman, M.S.3
-
35
-
-
84929117400
-
Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: subgroup analysis of the MCL-001 study
-
ASCO Annual Meeting Abstracts
-
Williams ME, Goy A, Sinha R et al. Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: subgroup analysis of the MCL-001 study. J Clin Oncol 2013; 31: (suppl; Abstract 8534; ASCO Annual Meeting Abstracts).
-
(2013)
J Clin Oncol
, vol.31
-
-
Williams, M.E.1
Goy, A.2
Sinha, R.3
-
36
-
-
84928022568
-
Updated efficacy and safety, and exploratory Ki-67 results for the MCL-001 study of lenalidomide in mantle cell lymphoma patients who relapsed or were refractory to bortezomib
-
ASH Annual Meeting Abstracts
-
Goy A, Williams ME, Besisik SK et al. Updated efficacy and safety, and exploratory Ki-67 results for the MCL-001 study of lenalidomide in mantle cell lymphoma patients who relapsed or were refractory to bortezomib. Blood 2013; 122 (Abstract 3057; ASH Annual Meeting Abstracts).
-
(2013)
Blood
, vol.122
-
-
Goy, A.1
Williams, M.E.2
Besisik, S.K.3
-
37
-
-
80053502780
-
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-celllike than in germinal center B-cell-like phenotype
-
Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-celllike than in germinal center B-cell-like phenotype. Cancer 2011; 117: 5058-5066.
-
(2011)
Cancer
, vol.117
, pp. 5058-5066
-
-
Hernandez-Ilizaliturri, F.J.1
Deeb, G.2
Zinzani, P.L.3
-
38
-
-
84899427423
-
Lenalidomide is effective in heavily pretreated non-Hodgkin lymphoma (NHL): analysis of a retrospective data collection
-
ASH Annual Meeting Abstracts
-
Rigacci L, Vitolo U, Cox MC et al. Lenalidomide is effective in heavily pretreated non-Hodgkin lymphoma (NHL): analysis of a retrospective data collection. Blood 2012; 120 (Abstract 3694; ASH Annual Meeting Abstracts).
-
(2012)
Blood
, vol.120
-
-
Rigacci, L.1
Vitolo, U.2
Cox, M.C.3
-
39
-
-
23844435619
-
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model
-
Hernandez-Ilizaliturri FJ, Reddy N, Holkova B et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005; 11: 5984-5992.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 5984-5992
-
-
Hernandez-Ilizaliturri, F.J.1
Reddy, N.2
Holkova, B.3
-
40
-
-
36849024949
-
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo
-
Reddy N, Hernandez-Ilizaliturri FJ, Deeb G et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008; 140: 36-45.
-
(2008)
Br J Haematol
, vol.140
, pp. 36-45
-
-
Reddy, N.1
Hernandez-Ilizaliturri, F.J.2
Deeb, G.3
-
41
-
-
84863107308
-
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
-
Wang M, Fayad L, Wagner-Bartak N et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012; 13: 716-723.
-
(2012)
Lancet Oncol
, vol.13
, pp. 716-723
-
-
Wang, M.1
Fayad, L.2
Wagner-Bartak, N.3
-
42
-
-
84927730011
-
Sustained remission with the combination biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma: a multicenter phase II study report
-
ASH Annual Meeting Abstracts
-
Ruan J, Martin P, Shah BD et al. Sustained remission with the combination biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma: a multicenter phase II study report. Blood 2014; 124 (21; Abstract 625; ASH Annual Meeting Abstracts).
-
(2014)
Blood
, vol.124
, Issue.21
-
-
Ruan, J.1
Martin, P.2
Shah, B.D.3
-
43
-
-
84883742025
-
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
-
Wang M, Fowler N, Wagner-Bartak N et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013; 27: 1902-1909.
-
(2013)
Leukemia
, vol.27
, pp. 1902-1909
-
-
Wang, M.1
Fowler, N.2
Wagner-Bartak, N.3
-
44
-
-
84857654592
-
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial
-
Zinzani PL, Pellegrini C, Gandolfi L et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 2011; 11: 462-466.
-
(2011)
Clin Lymphoma Myeloma Leuk
, vol.11
, pp. 462-466
-
-
Zinzani, P.L.1
Pellegrini, C.2
Gandolfi, L.3
-
45
-
-
84889004860
-
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients
-
Zinzani PL, Pellegrini C, Derenzini E et al. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. Hematol Oncol 2013; 31: 223-224.
-
(2013)
Hematol Oncol
, vol.31
, pp. 223-224
-
-
Zinzani, P.L.1
Pellegrini, C.2
Derenzini, E.3
-
46
-
-
84898467895
-
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma
-
Tuscano JM, Dutia M, Chee K et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol 2014; 165: 375-381.
-
(2014)
Br J Haematol
, vol.165
, pp. 375-381
-
-
Tuscano, J.M.1
Dutia, M.2
Chee, K.3
-
47
-
-
84868193664
-
CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma
-
ASCO Annual Meeting Abstracts
-
Leonard J, Jung SH, Johnson JL et al. CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. J Clin Oncol 2012; 30 (Abstract 8000; ASCO Annual Meeting Abstracts).
-
(2012)
J Clin Oncol
, vol.30
-
-
Leonard, J.1
Jung, S.H.2
Johnson, J.L.3
-
48
-
-
84901721963
-
CALGB 50803(ALLIANCE): a phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma
-
ICML Abstracts
-
Martin P, Jung S, Johnson J et al. CALGB 50803(ALLIANCE): a phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. Hematol Oncol 2013; 31 (suppl I; 117 Abstract 063; ICML Abstracts).
-
(2013)
Hematol Oncol
, vol.31
, pp. 117
-
-
Martin, P.1
Jung, S.2
Johnson, J.3
-
49
-
-
84908574357
-
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
-
Fowler NH, Davis RE, Rawal S et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014; 15: 1311-1318.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1311-1318
-
-
Fowler, N.H.1
Davis, R.E.2
Rawal, S.3
-
50
-
-
84857740069
-
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
-
Zaja F, De Luca S, Vitolo U et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012; 97: 416-422.
-
(2012)
Haematologica
, vol.97
, pp. 416-422
-
-
Zaja, F.1
De Luca, S.2
Vitolo, U.3
-
51
-
-
84891868901
-
Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas
-
Ahmadi T, Chong EA, Gordon A et al. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer 2014; 120: 222-228.
-
(2014)
Cancer
, vol.120
, pp. 222-228
-
-
Ahmadi, T.1
Chong, E.A.2
Gordon, A.3
-
52
-
-
84929119124
-
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)
-
Morrison VA, Jung SH, Johnson J et al. Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501). Leuk Lymphoma 2014; 1-14. doi:10.3109/10428194.2014.938333.
-
(2014)
Leuk Lymphoma
, pp. 1-14
-
-
Morrison, V.A.1
Jung, S.H.2
Johnson, J.3
-
53
-
-
84909967627
-
Rituximab, lenalidomide, and bortezomib in the first-line or second-line treatment of patients with mantle cell lymphoma: a phase I/II trial
-
ASH Annual Meeting Abstracts
-
Flinn IW, Mainwaring M, Peacock N et al. Rituximab, lenalidomide, and bortezomib in the first-line or second-line treatment of patients with mantle cell lymphoma: a phase I/II trial. Blood 2012; 120 (Abstract 2748; ASH Annual Meeting Abstracts).
-
(2012)
Blood
, vol.120
-
-
Flinn, I.W.1
Mainwaring, M.2
Peacock, N.3
-
54
-
-
84921764017
-
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study
-
Nowakowski GS, LaPlant B, Macon WR et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol 2014; 33: 251-257.
-
(2014)
J Clin Oncol
, vol.33
, pp. 251-257
-
-
Nowakowski, G.S.1
LaPlant, B.2
Macon, W.R.3
-
55
-
-
84983215647
-
Lenalidomide in combination with RCHOP (R2-CHOP) in patients with high burden follicular lymphoma: Phase 2 study
-
ASH Annual Meeting Abstracts
-
Tilly H, Morschhauser F, Casasnovas O et al. Lenalidomide in combination with RCHOP (R2-CHOP) in patients with high burden follicular lymphoma: Phase 2 study. Blood 2013; 122 (Abstract 248; ASH Annual Meeting Abstracts).
-
(2013)
Blood
, vol.122
-
-
Tilly, H.1
Morschhauser, F.2
Casasnovas, O.3
-
56
-
-
84901391325
-
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial
-
Vitolo U, Chiappella A, Franceschetti S et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 2014; 15: 730-737.
-
(2014)
Lancet Oncol
, vol.15
, pp. 730-737
-
-
Vitolo, U.1
Chiappella, A.2
Franceschetti, S.3
-
57
-
-
84929093161
-
Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: preliminary results from the Nordic Lymphoma Group MCL4 (LENABERIT) phase I-II trial
-
ASH Annual Meeting Abstracts
-
Jerkeman M, Albertsson-Lindblad A, Kolstad A et al. Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: preliminary results from the Nordic Lymphoma Group MCL4 (LENABERIT) phase I-II trial. Blood 2013; 122 (Abstract 4377; ASH Annual Meeting Abstracts).
-
(2013)
Blood
, vol.122
-
-
Jerkeman, M.1
Albertsson-Lindblad, A.2
Kolstad, A.3
-
58
-
-
36349023319
-
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
-
Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
-
(2007)
N Engl J Med
, vol.357
, pp. 2123-2132
-
-
Dimopoulos, M.1
Spencer, A.2
Attal, M.3
-
59
-
-
36349010285
-
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
-
Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.
-
(2007)
N Engl J Med
, vol.357
, pp. 2133-2142
-
-
Weber, D.M.1
Chen, C.2
Niesvizky, R.3
-
60
-
-
84867329976
-
Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines
-
Cosenza M, Civallero M, Grisendi G et al. Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines. Ann Hematol 2012; 91: 1613-1622.
-
(2012)
Ann Hematol
, vol.91
, pp. 1613-1622
-
-
Cosenza, M.1
Civallero, M.2
Grisendi, G.3
-
61
-
-
83555173455
-
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study
-
Nowakowski GS, LaPlant B, Habermann TM et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia 2011; 25: 1877-1881.
-
(2011)
Leukemia
, vol.25
, pp. 1877-1881
-
-
Nowakowski, G.S.1
LaPlant, B.2
Habermann, T.M.3
-
62
-
-
84873571469
-
Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma
-
Tilly H, Morschhauser F, Salles G et al. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia 2013; 27: 252-255.
-
(2013)
Leukemia
, vol.27
, pp. 252-255
-
-
Tilly, H.1
Morschhauser, F.2
Salles, G.3
-
63
-
-
84887011781
-
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi
-
Chiappella A, Tucci A, Castellino A et al. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica 2013; 98: 1732-1738.
-
(2013)
Haematologica
, vol.98
, pp. 1732-1738
-
-
Chiappella, A.1
Tucci, A.2
Castellino, A.3
-
64
-
-
84880259494
-
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial
-
Hitz F, Fischer N, Pabst T et al. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Ann Hematol 2013; 92: 1033-1040.
-
(2013)
Ann Hematol
, vol.92
, pp. 1033-1040
-
-
Hitz, F.1
Fischer, N.2
Pabst, T.3
-
65
-
-
84862212752
-
Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: results from the phase I portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) trial
-
ASH Annual Meeting Abstracts
-
Jerkeman M, Kolstad A, Laurell A et al. Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: results from the phase I portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) trial. Blood 2011; 118 (Abstract 2700; ASH Annual Meeting Abstracts).
-
(2011)
Blood
, vol.118
-
-
Jerkeman, M.1
Kolstad, A.2
Laurell, A.3
-
66
-
-
79958043675
-
-
Bethesda, MD: National Cancer Institute 2015. based on November 2013 SEER data submission, posted to the SEER website, April 2014
-
Howlader N, Noone AM, Krapcho M et al. (eds). SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute 2015. http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER website, April 2014.
-
SEER Cancer Statistics Review, 1975-2007
-
-
Howlader, N.1
Noone, A.M.2
Krapcho, M.3
-
67
-
-
79960431409
-
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified
-
Zinzani PL, Pellegrini C, Broccoli A et al. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma 2011; 52: 1585-1588.
-
(2011)
Leuk Lymphoma
, vol.52
, pp. 1585-1588
-
-
Zinzani, P.L.1
Pellegrini, C.2
Broccoli, A.3
-
68
-
-
81055123994
-
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
-
Fehniger TA, Larson S, Trinkaus K et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011; 118: 5119-5125.
-
(2011)
Blood
, vol.118
, pp. 5119-5125
-
-
Fehniger, T.A.1
Larson, S.2
Trinkaus, K.3
|